ACSL4-deficient CD8+ T cells were protected from the threat of rsl3-induced ferroptosis but also resulted in functional defects of CD8+ T cells, allowing cancer cells to evade specific killing by CD8+ T cells. This evidence concerns the gene CD8A and cancer.